key: cord-0796663-4ck5n9at
authors: Mousavi, Seyedeh Zahra; Rahmanian, Mojdeh; Sami, Ashkan
title: A connectivity map-based drug repurposing study and integrative analysis of transcriptomic profiling of SARS-CoV-2 infection
date: 2020-10-29
journal: Infect Genet Evol
DOI: 10.1016/j.meegid.2020.104610
sha: dd09abcb69459dc4c3e638556bc5f71b22678b13
doc_id: 796663
cord_uid: 4ck5n9at

AIMS: The recent outbreak of COVID-19 has become a global health concern. There are currently no effective treatment strategies and vaccines for the treatment or prevention of this fatal disease. The current study aims to determine promising treatment options for the COVID-19 through a computational drug repurposing approach. MATERIALS AND METHODS: In this study, we focus on differentially expressed genes (DEGs), detected in SARS-CoV-2 infected cell lines including “the primary human lung epithelial cell line NHBE” and “the transformed lung alveolar cell line A549”. Next, the identified DEGs are used in the connectivity map (CMap) analysis to identify similarly acting therapeutic candidates. Furthermore, to interpret lists of DEGs, pathway enrichment and protein network analysis are performed. Genes are categorized into easily interpretable pathways based on their biological functions, and overrepresentation of each pathway is tested in comparison to what is expected randomly. KEY FINDINGS: The results suggest the effectiveness of lansoprazole, folic acid, sulfamonomethoxine, tolnaftate, diclofenamide, halcinonide, saquinavir, metronidazole, ebselen, lidocaine and benzocaine, histone deacetylase (HDAC) inhibitors, heat shock protein 90 (HSP90) inhibitors, and many other clinically approved drugs as potent drugs against COVID-19 outbreak. SIGNIFICANCE: Making new drugs remain a lengthy process, so the drug repurposing approach provides an insight into the therapeutics that might be helpful in this pandemic. In this study, pathway enrichment and protein network analysis are also performed, and the effectiveness of some drugs obtained from the CMap analysis has been investigated according to previous researches.

Transcriptomic Profiling.

Coronavirus disease 2019 (COVID- 19) is an emerging global health concern. It initially appeared in December 2019 in China with cases of unknown origin pneumonia.

Subsequently, a novel betacoronavirus was isolated from the throat sample of a patient, furtherly demonstrated [8] . It was also proposed during the COVID-19 pandemic as a potential therapeutic agent, furtherly confirmed by in vitro experiments [9] . Although some clinical trials have been conducted to evaluate its effectiveness for treating patients, the results were inconsistent [10] . In a randomized, double-blind, placebocontrolled clinical trial conducted by Beigel et al. [11] , 1063 COVID-19 patients from 10 countries were enrolled to receive remdesivir or placebo infusion. Results showed remdesivir can significantly improve the clinical recovery of hospitalized patients (NCT04280705). However, Wang et al. [12] have conducted a double-blind, multicenter trial at 10 hospitals in China between Feb 6, 2020, and March 12, 2020. 237 confirmed COVID-19 patients have participated in this trial and were randomly grouped in a 2:1 ratio to cases receiving intravenous remdesivir and controls receiving placebo infusions for 10 days. Results revealed prescribing remdesivir for severe COVID-19 patients is not associated with significant clinical benefits (NCT04257656).

Lopinavir-ritonavir combination (Kaletra), two HIV protease inhibitors, has been under investigation for COVID-19 treatment since this pandemic [13] . In a randomized openlabel trial, 199 COVID-19 patients were evaluated for the effects of lopinavir-ritonavir treatment in comparison to standard supportive care. Results showed no benefit with lopinavir-ritonavir treatment beyond standard care (Chinese Clinical Trial Register number: ChiCTR2000029308) [14] . In another exploratory randomized controlled trial, 86 COVID-19 patients were assigned to receive lopinavir-ritonavir or arbidol or no antiviral medication. Results revealed the little benefit of antiviral medications over supportive care (NCT04252885) [15] .

Besides, some other antiviral, anti-inflammatory, antineoplastic, and antiparasitic agents have been proposed and undergone in vitro and in vivo experiments; however, results were inconsistent and controversial [16] .

Different approaches are available for drug repurposing and one of the most commonly used strategies is signature matching. It is based on comparing the transcriptomic signature of a specific disease with the unique signature of a drug resulting in the creation of a connectivity map (CMap) [17] .

The CMap concept was initially presented by Lamb et al. [18, 19] in 2006. They generated a large-scale genomic signatures database to translate gene functions, diseases, and drug actions into the same language. It begins with identifying gene expression signature of a specific disease that contains a list of differentially expressed genes (DEGs), genes that are significantly up-or down-regulated in a specific disorder in comparison to its control sample. This signature is then compared with a collection of gene expression signatures of cell lines treated with various small molecules. The result of signature matching for each pair is shown with a connectivity score ranging from -1 to +1. A negative connectivity score reflects the potential effect of that small molecule to reverse the signature of a specific disorder. Therefore, it can be used as a therapeutic option.

Since the introduction of CMap, this method has been applied in pharmacological research to define drug-disease connections [20, 21] . In 2016, So et al. [22] 

The NCBI (National Center for Biotechnology Information) Gene Expression Omnibus (GEO) database (http://www.ncbi.nlm.nih.gov/geo/) was used to identify microarray datasets [27] . The GEO database was manually searched using the terms -SARS-CoV-2‖ or -COVID-19‖. The collected datasets were further selected if they met the following [30] .

Studies have shown that statistical cut-offs for the selection of DEGs can significantly modulate the results of microarray analysis. That means applying more stringent cut-offs can select only the genes which vary significantly among the others and genes with subtle changes are not considered [31] . Therefore, we aimed to conduct a microarray study with different criteria. First, genes with an adjusted p value< 0.05 irrespective of the fold-change were identified as DEGs and selected for further analysis. Then, more stringent criteria for selection of the DEGs were applied (i.e., adj. p value< 0.05 and |fold-change| > 2).

The CMap library is a collection of gene-expression profiles of drug-treated human cancer cells, which has been widely used for investigation of polypharmacology and drug approved drugs, this database has become a powerful tool for drug repurposing [33] . Gene expression signatures of SARS-CoV-2 infected cell lines, lists of significantly up-and down-regulated genes, resulting from the GSE147507 dataset were used as the input data and compared with gene expression signatures of available CMap drugs by using a patternmatching algorithm based on the non-parametric rank-ordered Kolmogorov-Smirnov statistics [34] to determine connectivity scores [35] . Connectivity scores were analysed for each drug-disease pair to investigate the correlation between the drug and the COVID-19

signature. Drugs with significant negative connectivity scores can potentially reverse the gene expression profile of SARS-CoV-2 infection and can be used as therapeutic options.

Pathway enrichment analysis was performed with the Metascape web tool (http://metascape.org) to determine whether the identified DEGs are enriched for specific biological functions. Metascape is a web-based portal integrating over 40 bioinformatic knowledgebases within one portal, implementing an automated analysis workflow including conversion, gene annotation, membership, and enrichment analysis [36] . Pathway enrichment analysis was carried out for up-regulated and down-regulated genes of NHBE and A549 cell lines separately using Metascape with the following ontology sources:

KEGG Pathway, GO Biological Processes, Reactome Gene Sets, Canonical Pathways, and CORUM. Terms with a p-value < 0.01, a minimum count of 3, and an enrichment factor > 1.5 were grouped into clusters based on their membership similarities. Kappa scores [37] are used as the similarity metric and sub-trees with a similarity of > 0. 3 method was applied to identify closely connected network components [40] . Furthermore, pathway enrichment analysis was applied to each MCODE components independently.

Terms were then ranked based on the p-value and the three best-scoring terms by p-value were shown as the functional description of the corresponding components.

We aimed to study the genes differentially expressed upon SARS-CoV-2 infection, in NHBE cells and A549 cells separately. First, all genes with adjusted p-value<0.05, these two criteria, a set of 72 genes (64 genes were up-regulated and 8 genes were downregulated) from NHBE cells, and 46 genes (44 genes were up-regulated and 2 genes were down-regulated) from A549 cells were identified that showed evidence for differential expression. (supplementary file 3). These identified lists of DEGs were further analysed through CMap study separately.

For the CMap analysis, PharmacoGx was used. Lists of DEGs identified in the previous step were applied as the input data and compared with CMap compounds library.

Compounds with p-value<0.05 and negative connectivity scores were selected and analysed. First, based on genes with adjusted p-value<0.05, 57 and 25 compounds were shown to significantly reverse genomic signatures of SARS-CoV-2 infected NHBE and A549 cells, respectively. After applying a more stringent selection of DEGs, results were limited to 8 and 6 effective compounds against infected NHBE and A549 cells, respectively. Table 1 summarizes the results of the CMap analysis.

To analyse the biological process of identified DEGs in SARS-CoV-2 infected cells, the The newly emerged COVID-19 has become a major global public health concern.

However, complete life cycle details of SARS-CoV-2 and host response are not properly known yet. As long as our knowledge of this virus is limited, designing effective novel treatments are almost impossible. Transcriptome analysis of SARS-CoV-2 infected cells can aid our understanding of this virus and accelerate the discovery of novel therapies.

In this study, we conducted a drug repurposing strategy based on CMap to identify were created. However, lacking standard frameworks for annotation, storage, access, and analysis challenged the use of these datasets. Therefore, unifying integrative platforms could remove biases of different sources, profiling platforms, and cell-specific differences.

PharmacoGx is one of the few or even only integrative platforms developed for this reason.

Some of the top-scoring compounds resulting from the CMap analysis have been discussed:

Lansoprazole, a proton pump inhibitor (PPI), is another candidate. Watanabe et al. [44] have published an article in 2020, confirming potential antiviral properties of prazoles against different viruses such as HIV, Ebola virus (EBOV), and Epstein-Barr virus (EBV).

Bojkova et al. [45] have conducted in vitro experiments to identify novel inhibitors of SARS-CoV-2 replication and they showed the potential of omeprazole, another PPI, to increase the antiviral activity of remdesivir. It is known that inhibiting ATPase proton pumps with medications such as PPI may interfere with the acidification of endosomal pathways that seems an essential step for coronavirus infectivity. Chloroquine and hydroxychloroquine also are shown to have the same effects as prazoles to increase lysosomal PH [46] . Besides this, other mechanisms should also be considered.

Folic acid is another option. Some previous studies have suggested folic acid as an adjunctive therapy [47] . Besides immune-boosting properties, folic acid can be used as an inhibitor of furin activity, an enzyme responsible for SARS-CoV-2 spike protein cleavage [48] . Therefore, it can be considered as a prophylactic or therapeutic candidate for COVID-19, especially in initial phases. In silico studies have also proposed folic acid as a potential inhibitor of SARS-CoV-2 main protease [49] . 

Another option is tolnaftate, a synthetic over-the-counter antifungal agent that inhibits also showed a significant binding affinity of terbinafine to SARS-CoV-2 PLpro.

Besides, SARS-CoV-2 infected patients are at increased risk of fungal co-infections such as pulmonary aspergillosis or candidiasis [63, 64] . Repurposing a drug with both antifungal and antiviral properties would be a more promising option.

Another top-scoring compound is diclofenamide with connectivity-score= -0. 59 Solaimanzadeh [66] has reviewed features of COVID-19 pneumonia in parallel to high altitude pulmonary edema (HAPE) and revealed substantial similarities between these two conditions leading to ARDS. Therefore, it was hypothesized that medications commonly used in HAPE including acetazolamide, nifedipine, etc., can be effective for COVID-19 symptomatic therapy. In another study, Geier et al. [67] , have also provided some evidence consistent with the previously mentioned study to confirm the potential effectiveness of carbonic anhydrase inhibitors for COVID-19 treatment. However, further investigations on the effectiveness of these compounds are needed.

One 

An approved drug with one of the highest connectivity scores is saquinavir, an HIV protease inhibitor [76] . Virtual screening of clinically approved drugs has shown saquinavir as a potential inhibitor of SARS-CoV-2 main protease, RNA-dep RNA polymerase, and other non-structural proteins (nsp) [77, 78] . Saquinavir can also suppress SARS-CoV-2 replication based on in vitro models in less than 10µM concentration [79] . Other drugs of this group such as lopinavir and ritonavir are currently used as COVID-19 treatment.

Journal Pre-proof

Another important drug is metronidazole, a commonly used antibiotic [80] . Some recent studies have proposed metronidazole as an addition to the COVID-19 treatment regimen due to its immunomodulatory effects. Metronidazole can decrease the level of inflammatory cytokines which are increased during COVID-19 infection [81] . Chakraborty et al. [82] have proposed adding anaerobe-specific antibiotics such as metronidazole to COVID-19 treatment due to evidence of overexpression of anaerobic bacteria in COVID-19 patients.

Another top-scoring drug is ebselen. Ebselen is a small molecule with antioxidant, antiinflammatory, and cytoprotective features [83] . Previous computer-aided studies have revealed ebselen as a strong inhibitor of SARS-CoV-2 main protease, furtherly was approved through cell-based studies [84] . It is also known that ebselen can covalently bind to the Zn-bound/catalytic cysteines in SARS-CoV-2 papain-like protease (PLpro) and nsp10, two critical proteins for viral replication, to inhibit them [85] . In the last two decades, different analogs of ebselen were synthesized as antiviral agents [86] . These data strongly emphasize the clinical potential of ebselen for treating COVID-19 patients.

Two resulting compounds are lidocaine and benzocaine, local anesthetics with the same In another article, Finnerty et al. [91] have discussed the role of neutrophil extracellular traps (NETs), web-like structures of DNA and proteins produced by neutrophils as an alternative way to kill circulating pathogens, in COVID-19 pathogenesis. Excessive production of NETs in COVID-19 patients would be associated with a hypercoagulable state, myocardial infarction, sepsis, respiratory distress, and contributing to cytokine storm.

Since previous evidence has shown that local anesthetics can inhibit the production of NETs in patients undergoing surgery, they can be proposed as novel candidates to reduce COVID-19 severity and further complications. More studies are needed to confirm this hypothesis.

Another drug is aminocaproic acid, a plasminogen activator inhibitor (PAI) [92] . It is known that PAIs can inhibit other membrane-anchored serine proteases such as transmembrane serine protease 2 (TMPRSS2), a critical factor for cell entry of SARS-CoV-2 [93] . Therefore, they can be used as a therapeutic or even prophylactic agent for COVID- Hypoprolactinemia can cause lymphocytic depletion leading to nosocomial infections.

Using dopamine antagonists to enhance serum prolactin levels has been shown effective for HIV control by increasing lymphocyte proliferation. It can also boost the innate immune response by stimulating NK cells, neutrophils, and macrophages. Chlorpromazine, another dopamine antagonist, has also been suggested as a therapeutic candidate for COVID-19

with unknown antiviral mechanisms [97] . [100] . Therefore, these medications and other drugs with the same mechanisms would be potent adjunctive therapies for COVID-19.

Monorden or radicicol is a heat shock protein 90 (HSP90) inhibitor [101]. Connor et al.

[102] in 2007 showed that HSP90 is essential for viral replication and its inhibitors such as radicicol or geldanamycin could block the replication of RNA viruses. A recent study conducted by Wyler et al. [103] has examined the effect of HSP90 inhibitors on SARS-CoV-2 based on in vitro models and proposed this group as potent antiviral and antiinflammatory agents.

Sodium phenylbutyrate is a histone deacetylase (HDAC) inhibitor [104] . They act as epigenetic modulators and regulate expression of genes involved in the cell cycle, proliferation, differentiation, and also inflammation [105] . A number of these compounds have been suggested for SARS-CoV-2. In vitro experiments have shown an inhibitory effect of valproate, an HDAC inhibitor, on the NF-KB pathway, and subsequently suppressing TNF-α and IL 6 [106] . Besides, they can be used as antifibrotic agents in pulmonary fibrosis [107] . Other immunosuppressive agents such as TNF inhibitors, JAK inhibitors, etc.

should also be considered. Another study has evaluated the effect of anti-CXCL8 agent BMS-986253 on cancer patients with COVID-19. Besides, inhibiting CXCR2, a cytokine receptor, has improved pulmonary inflammatory disease in an influenza-induced lung injury mouse model [123] .

Therefore, more studies should be conducted to evaluate usage of CXCR1 and CXCR2

J o u r n a l P r e -p r o o f 

None declared. study design, in the collection, analysis, and interpretation of data; in the writing of the manuscript; and in the decision to submit the manuscript for publication. J o u r n a l P r e -p r o o f Table 2 . Pathway enrichment analysis applied to MCODE 1-3 components represented in figure 3 independently, and the three most significant terms by p-value represent the functional description of the corresponding components. Table 3 . Pathway enrichment analysis applied to MCODE 1-3 components presented in figure 4 independently, and the three most significant terms by p-value represent the functional description of the corresponding components. 

A novel coronavirus outbreak of global health concern. The Lancet

Identification of a novel coronavirus causing severe pneumonia in human: a descriptive study

Coronavirus infections-more than just the common cold

A Rapid Systematic Review of Clinical Trials Utilizing Chloroquine and Hydroxychloroquine as a Treatment for COVID-19. Academic Emergency Medicine

Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro

COVID-19 drug repurposing: A review of computational screening methods, clinical trials, and protein interaction assays

Remdesivir for the treatment of Covid-19-preliminary report

Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. The Lancet

A trial of lopinavirritonavir in adults hospitalized with severe Covid-19

Efficacy and safety of lopinavir/ritonavir or arbidol in adult patients with mild/moderate COVID-19: an exploratory randomized controlled trial

Drug repurposing and cytokine management in response to COVID-19: a review

Drug repurposing: progress, challenges and recommendations

The Connectivity Map: a new tool for biomedical research

Applications of Connectivity Map in drug discovery and development

A review of connectivity map and computational approaches in pharmacogenomics

When GWAS meets the Connectivity Map: drug repositioning for seven psychiatric disorders

A drug repositioning approach identifies tricyclic antidepressants as inhibitors of small cell lung cancer and other neuroendocrine tumors

Weighted gene co-expression network analysis and connectivity map identifies lovastatin as a treatment option of gastric cancer by inhibiting HDAC2

Gene expression profiling coupled with Connectivity Map database mining reveals potential therapeutic drugs for Hirschsprung disease

Using Connectivity map data and PharmacoGx R package to find drugs against coronaviruses

mining tens of millions of expression profiles-database and tools update

Imbalanced host response to SARS-CoV-2 drives development of COVID-19

Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2

Controlling the false discovery rate: a practical and powerful approach to multiple testing

Fold change and pvalue cutoffs significantly alter microarray interpretations

PharmacoGx: an R package for analysis of large pharmacogenomic datasets

Connections in pharmacology: innovation serving translational medicine. Drug discovery today

Nonparametric statistical methods

Systematic evaluation of connectivity map for disease indications

Metascape provides a biologist-oriented resource for the analysis of systems-level datasets

A coefficient of agreement for nominal scales

Biostatistical Analysis

An automated method for finding molecular complexes in large protein interaction networks

Transcriptional landscape of SARS-CoV-2 infection dismantles pathogenic pathways activated by the virus, proposes unique sex-specific differences and predicts tailored therapeutic strategies

A New Advanced In Silico Drug Discovery Method for Novel Coronavirus (SARS-CoV-2) with Tensor Decomposition-Based Unsupervised Feature Extraction. Preprints

Evaluation of Connectivity Map shows limited reproducibility in drug repositioning

Selective targeting of Virus Replication by proton pump inhibitors

SARS-CoV-2 and SARS-CoV differ in their cell tropism and drug sensitivity profiles

The role of folic acid in the management of respiratory disease caused by COVID-19

two Natural Compounds and Folic acid as Potential Inhibitors of 2019-novel coronavirus Main Protease (2019-nCoVMpro), molecular docking and SAR study

Antiviral activity of organic molecules having sulfonamide moiety: An insight of recent research

Protease inhibitors of the sulfonamide type: anticancer, antiinflammatory, and antiviral agents

Antiviral sulfonamide derivatives. Mini reviews in medicinal chemistry

Screening of Therapeutic Agents for COVID-19 Using Machine Learning and Ensemble Docking Studies. The journal of physical chemistry letters

silico Drug Repurposing for COVID-19: Targeting SARS-CoV-2 Proteins through Docking and Consensus Ranking. Molecular Informatics

Drug Repositioning Suggests a Role for the Heat Shock Protein 90 Inhibitor Geldanamycin in Treating COVID-19 Infection

Ligands Based Drug Design for Covid 19-A

Multi-Faceted Approach using Ligand Design, Molecular Docking and Binding Probability Calculation

Amphotericin B as antiviral drug: Possible efficacy against COVID-19

Lysosomotropic active compoundshidden protection against COVID-19/SARS-CoV-2 infection?

Potential inhibitors against papain-like protease of novel coronavirus (COVID-19) from FDA approved drugs

Diagnosing COVID-19-associated pulmonary aspergillosis

COVID-19 associated invasive candidiasis. The Journal of Infection

rationale for their utilization as adjunctive countermeasures in the treatment of coronavirus disease 2019 (COVID-19)

COVID-19): Important considerations regarding novel treatment strategies to reduce mortality

Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease

Early Short Course Corticosteroids in Hospitalized Patients with COVID-19. medRxiv

Effect of dexamethasone in hospitalized patients with COVID-19: preliminary report. medRxiv

Role of corticosteroid in the management of COVID-19: A systemic review and a Clinician's perspective

Inhaled corticosteroids and COVID-19: a systematic review and clinical perspective

Inhibitory effects of glycopyrronium, formoterol, and budesonide on coronavirus

HCoV-229E replication and cytokine production by primary cultures of human nasal and tracheal epithelial cells. Respiratory Investigation

The inhaled corticosteroid ciclesonide blocks coronavirus RNA replication by targeting viral NSP15. bioRxiv

A search for medications to treat COVID-19 via in silico molecular docking models of the SARS-CoV-2 spike glycoprotein and 3CL protease

Potential inhibitors targeting RNA-dependent RNA polymerase activity (NSP12) of SARS-CoV-2. Preprints

Nelfinavir inhibits replication of severe acute respiratory syndrome coronavirus 2 in vitro

Metronidazole; a Potential Novel Addition to the COVID-19 Treatment Regimen

Secondary infection by anaerobic bacteria possibly ensues a battle for oxygen in SARS-Cov2 infected patients: anaerobe-targeting antibiotics (like doxycycline/Metronidazole) to supplement Azithromycin in the treatment regimen of COVID19

Structure of Mpro from COVID-19 virus and discovery of its inhibitors

Multi-Targeting of Functional Cysteines in Multiple Conserved SARS-CoV-2 Domains by Clinically Safe Zn-ejectors

Azaanalogues of ebselen as antimicrobial and antiviral agents: synthesis and properties

Anti-inflammatory properties of local anesthetics and their present and potential clinical implications

Nebulized Lidocaine in COVID-19, An Hypothesis. Medical Hypotheses

A novel role for lidocaine in COVID-19 patients?

COVID-19 pandemic; transmembrane protease serine 2 (TMPRSS2) inhibitors as potential drugs. Translation: The University of

Novel hemagglutinin-based influenza virus inhibitors

Repurposing Prolactin as a Promising Immunomodulator for the Treatment of COVID-19: Are Common Antiemetics the Wonder Drug to Fight Coronavirus? Medical Hypotheses

Ontological and bioinformatic analysis of anti-coronavirus drugs and their Implication for drug repurposing against COVID-19

Angiotensin converting enzyme 2 as the molecular bridge between epidemiologic and clinical features of COVID-19

Antiviral activity and RNA

Bulk and single-cell gene expression profiling of SARS-CoV-2 infected human cell lines identifies molecular targets for therapeutic intervention

Erasers of histone acetylation: the histone deacetylase enzymes. Cold Spring Harbor Perspectives in Biology

Repurposing valproate to prevent acute respiratory distress syndrome/acute lung injury in COVID-19: A review of immunomodulatory action

HDAC inhibitors as antifibrotic drugs in cardiac and pulmonary fibrosis

Statins suppress Ebola virus infectivity by interfering with glycoprotein processing

Statins and the COVID-19 main protease: in silico evidence on direct interaction

A metabolic modeling

The pathogenesis and treatment of theCytokine Storm'in COVID-19

On the alert for cytokine storm: Immunopathology in COVID-19

Cytokine storm in COVID-19-Immunopathological mechanisms, clinical considerations, and therapeutic approaches: The REPROGRAM Consortium position paper

Effect of regular intravenous immunoglobulin therapy on prognosis of severe pneumonia in patients with COVID-19. The Journal of infection

Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study. The Lancet Rheumatology

Anakinra for severe forms of COVID-19: a cohort study. The Lancet Rheumatology

Tocilizumab in patients with severe COVID-19: a retrospective cohort study

Tocilizumab treatment in COVID-19: A single center experience

Effective treatment of severe COVID-19 patients with tocilizumab

The cytokine storm in COVID-19: an overview of the involvement of the chemokine/chemokine-receptor system

Blocking inflammation on the way: Rationale for CXCR2 antagonists for the treatment of COVID-19

Coronavirus infections and immune responses

Impaired type I interferon activity and exacerbated inflammatory responses in severe Covid-19 patients. medRxiv

Type 1 interferons as a potential treatment against COVID-19

This research was partly funded through a research grant from Iran's National Elites